Suppression of fumarate hydratase activity increases the efficacy of cisplatin-mediated chemotherapy in gastric cancer.
Hong-En YuFeng WangFang YuZhao-Lei ZengYun WangYun-Xin LuYing JinDe-Shen WangMiao-Zheng QiuHeng-Ying PuTie-Bang KangDan XieHuai-Qiang JuRui-Hua XuHui-Yan LuoPublished in: Cell death & disease (2019)
Gastric cancer (GC) is one of the most common malignancies worldwide. Due to the low rate of early detection, most GC patients were diagnosed as advance stages and had poor response to chemotherapy. Some studies found that Fumarate hydratase (FH) participated in the DNA damage response and its deficiency was associated with tumorigenesis in some cancers. In this study, we investigated the relationship between FH and cisplatin (CDDP) sensitivity in GC cell lines. We found that FH was the most significant gene which induced by CDDP treatment and the suppression of FH could enhance the cytotoxicity of CDDP. Miconazole Nitrate (MN) could inhibit FH activity and enhance the effect of CDDP in vitro and in vivo. We also investigated the significance of expression of FH in GC tissues. The FH expression, which was higher in GC tissues than in noncancerous tissues, was negatively associated with the prognosis of patients. Together, these results revealed that FH is a reliable indicator for response to CDDP treatment in GC and the inhibition of FH may be a potential strategy to improve the effects of CDDP-based chemotherapy.
Keyphrases
- end stage renal disease
- chronic kidney disease
- ejection fraction
- dna damage response
- poor prognosis
- newly diagnosed
- gene expression
- gas chromatography
- prognostic factors
- locally advanced
- nitric oxide
- squamous cell carcinoma
- patient reported outcomes
- copy number
- risk assessment
- young adults
- mass spectrometry
- drinking water
- genome wide
- binding protein
- single cell
- replacement therapy
- room temperature